Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mevidalen · 1 trial · 1 indication
iADRS assesses the impact of cognitive loss on everyday activities and provides a measure of global AD severity as a single summary score. It comprises of 2 underlying domains "cognitive ability" and "functional ability," and integrates the items in both the domains a single overall score ranging from 0 to 144, with lower scores indicating worse performance.
| Arm | Type | Description |
|---|---|---|
| Mevidalen (high dose) | EXPERIMENTAL | Mevidalen high dose administered orally. |
| Mevidalen (low dose) | EXPERIMENTAL | Mevidalen low dose administered orally. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| Mevidalen | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living. * Have MMSE score of 13 to 24. * Have eligibile plasma P-tau or historical evidence of AD pathology. * Have a relia...
Top 20 of 24 competitors
Mevidalen is an investigational small molecule being studied for the treatment of Alzheimer's disease. It is a Phase 2 investigational drug developed by Eli Lilly and Company. Mevidalen is not approved by the FDA and remains in clinical development.
Mevidalen is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 2 clinical development for Alzheimer's disease.
Mevidalen is in Phase 2 clinical development. It is an investigational drug for Alzheimer's disease and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed.
Mevidalen has been studied in a Phase 2 clinical trial with the identifier NCT06538116, titled 'A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease.' The trial enrolled 304 participants in the United States and Japan and has been completed.
Yes, Mevidalen is also known as LY3154207. The clinical trial NCT06538116, which studied Mevidalen in participants with Alzheimer's disease, refers to the drug by this alternative name.